jeffrey a. meyerhardt, md explains integration of stivarga and lonserf in later lines of treatment
Published 8 years ago • 242 plays • Length 1:45
Download video MP4
Download video MP3
Similar videos
-
1:41
jeffrey a. meyerhardt, md, explains matching mutations and markers to therapies in crc patients
-
0:58
jeffrey a. meyerhardt, md explains how os from primary site of tumor may impact treatment
-
0:53
jeffrey a. meyerhardt, md discusses the phase 3 calgb/swog 80405 study
-
1:05
jeffrey a. meyerhardt, md explains results from the phase 3 calgb/swog 80405 study
-
5:55
colorectal cancer – an introduction, with jeffrey a. meyerhardt, md, mph
-
1:31
jeffrey a. meyerhardt, md, explains which molecular tests help determine treatment approach
-
1:02
jeffrey a. meyerhardt, md, on whether regorafenib is becoming more tolerable for mcrc patients
-
0:51
philip philip, md explains how to integrate regorafenib and trifluridine for 2nd line mcrc treatment
-
5:16
rachael wall, 26 year old stage iv colorectal cancer survivor, says yes to hope!
-
1:10:29
the 2009 jeffrey m. trent lecture in cancer research - carol greider
-
16:20
6 meses de regorafenibe (stivarga)
-
2:56
jeffrey a. meyerhardt, md, talks about the dfci wellness study
-
1:01
jeffrey a. meyerhardt, md, discusses immunotherapy in msi-stable crc patients
-
1:50
jeffrey a. meyerhardt, md, on integrating immunotherapy into treatment regimens for gi cancer
-
1:43
jeffrey a. meyerhardt, md, discusses outcomes of the phase 2 study in braf mutated crc patients
-
1:11
jeffrey a. meyerhardt, md weighs in on the economic vs efficacy outcomes in calgb/swog 80405
-
0:42
jeffrey meyerhardt, md, mph, on dose escalation of regorafenib as a result of the redos study
-
1:22
jeffrey a. meyerhardt, md, talks about the dfci wellness study
-
1:34
jeffrey meyerhardt, md, on how immunotherapies are being studied in gastric & esophageal cancers
-
0:48
jeffrey meyerhardt, md, mph, discusses the length of adjuvant therapy for colorectal cancer patients
-
1:01
jeffrey a. meyerhardt, md on pd-1 or pd-l1 treatment strategies for msi-stable mcrc patients
-
1:27
tanios bekaii-saab, md, comments on dosing regorafenib (stivarga) in 3rd line treatment of mcrc
Clip.africa.com - Privacy-policy